anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Among Veterans receiving healthcare from the Veterans Health Administration (VA), there has been sharp rise in the number of veterans diagnosed with opioid use disorder (OUD). In 2013, 25,031 Veterans had OUD and in 2017, Veterans with OUD nearly tripled to 69,142.6 As the largest direct provider of addiction treatment nationally, VA has taken steps to increase access to medication treatment for OUD, which is recognized as an essential component of evidence-based care.

The treatment of OUD involves several FDA-approved, VA formulary medications including naltrexone, methadone, and buprenorphine/naloxone and buprenorphine (hereafter collectively termed buprenorphine). Strong evidence supports the treatment of OUD with medications, and they are the "gold standard" treatments for OUD. Medications for OUD have been shown to substantially decrease risk for all-cause mortality and overdose mortality in people with opioid use disorder. Unlike methadone, buprenorphine for OUD can be prescribed in office-based settings such as primary care, and buprenorphine delivered in primary care is associated with decreased opioid use, higher quality of care, and improved quality of life. Medication treatment includes dispensation of methadone and buprenorphine in licensed opioid treatment programs (OTPs) and prescriptions of buprenorphine and naltrexone in office-based settings. Because there are only 32 licensed OTPs in the VA, buprenorphine and naltrexone prescriptions are the means to improve access to medication treatment for Veterans with OUD. Uptake of medication treatment, however, has been slow and uneven in the VA. In 2017, 35% of Veterans diagnosed with OUD had received OUD medications.

In VISN19, rates of OUD and OUD treatment are low and heterogeneous across facilities and compared with the national average (35%), fewer patients with OUD are on OUD medications (21%) in VISN19. Multiple initiatives have been instituted to improve access to medication treatment for Veterans with OUD, particularly in non-specialty office-based settings. In 2007, VA introduced the Buprenorphine in the VA Initiative (BIV; Director Gordon), a national consult service, which aimed to improve care processes and patient outcomes associated with buprenorphine. In 2010, VA unrolled Academic Detailing program in which pharmacy specialists take on high-priority pharmaceutical education campaigns. An Academic Detailing campaign specifically targeting the treatment of opioid use disorder was initiated in 2017. Further improving access to evidence-based medication treatment of OUD remains a priority for VA and VISN19.
FIELD: medicine, pharmaceutics. SUBSTANCE: the suggested substance is isolated out of Scorzonera hispanica VSKK- VP N35. Cellular mass is extracted with an aqueous ethanol. Thickened extract is dissolved in chloroform: methanol: water system being 5: 6: 4. Substance-bearing fractions are isolated and dissolved in hexane: methanol system being 7: 4. The product obtained is purified by a liquid-liquid chromatography and crystallization out of ethanol. EFFECT: improved results in obtaining a substance of high immunomodulating action. 2 tbl
Laryngeal mask airways (LMAs) are in practice of anesthesia since early 1980s. Pediatric and neonatal patients (including ex-premature) have also been benefited by the use of LMA. There are many advantages of LMA over endotracheal tube (ETT) in pediatric patients like ease of insertion, securing airway rapidly, avoidance of muscle relaxants, reduced incidence of sore throat, post operative hoarseness and coughing at the time of extubation, greater hemodynamic and intraocular pressure (IOP) stability. LMA has been recognized internationally in control of airway in difficult and failed intubation.

There are different types of pediatric LMAs available e.g. I-gel, ProSeal, LMA supreme, LMA classic, LMA unique, LarySeal and Ambu. These devices differ morphologically from each other (silicone, polyvinyl chloride or soft gel). There have been several randomized controlled studies comparing different LMAs in adults, however, the literature is sparse in which such comparison has been made in patients with weight 10 kg or below.
Currently, outpatient psychiatric settings are plagued by long wait times and are often unable to accommodate all individuals seeking services. Furthermore, a lack of trained therapists in these settings means that many treatment seekers do not have access to empirically supported psychotherapeutic treatments such as cognitive behavioral therapy. "Beating the Blues" (BtB) is a computerized, internet-delivered, cognitive behavioral treatment for depression. BtB is highly scalable and might enable a larger proportion of individuals to receive cognitive behavioral therapy in a psychiatric setting while also reducing therapist time. Although computerized CBT interventions have proven effective in primary care settings, there is no research demonstrating the effectiveness of cCBT in secondary care settings in the United States. Thus the primary goal of the proposed research is to test the efficacy of BtB in a specialty care sample.

Patients presenting to these settings tend to have more severe and complex psychopathology than those presenting to primary care. Although BtB is likely effective, computerized treatments do carry a higher risk of dropout and non-response. Therefore, reliable and valid predictors of response are needed to determine who is most likely to respond to the treatment, versus who is likely to fail or drop out. Thus the second aim of the current proposal is to pilot an assessment procedure containing a number of potential predictors of cCBT response and investigate these predictors for inclusion in a larger validation study.

The current trial is a pilot study with a randomized waitlist control design with optional delayed treatment for individuals randomized to the waitlist condition. For the first phase, the investigators will enroll 90 treatment-seeking adults 18 or older recruited from a pool of individuals seeking outpatient psychiatric services at a hospital clinic. Sixty (n=60) individuals will be assigned immediate treatment group with BtB plus telephone and email support, and n=30 to the waitlist/delayed BtB plus telephone and email support group. Efficacy will be assessed over 8 weeks using the Hamilton Rating Scale for Depression (pre to post treatment) and the PHQ9 (measured at weeks 1-8). There will also be a 1-year follow-up survey with biweekly symptom assessments throughout the year for treatment responders (weeks 9-61). Potential predictors of outcome include demographics, CBT skills, personality measures, cognitive functioning, measures of attitudes and beliefs, social functioning, psychiatric comorbidity and depression illness characteristics, and psychophysiological measures. A second phase will enroll sixty individuals (n=60), who will be assigned immediate treatment group in order to validate the predictive model constructed during Phase 1.
Prepn. of a hyaluronic acid (HA) comprises (a) culturing, in a protein free medium, the HA-producing organism which is either hyaluronidase-negative or -inhibited under conditions to ensure an enhanced content of HA in the organism, (b) extracting HA from the culture solution, and (c) removing reactive proteins via protein binding filtration.  Pref. protein content is less than 1.25 mg/ml. Yield of HA is better than extraction from rooster combs. The HA can be used as a joint fluid replacement in animals and a fluid replacement in cosmetics.
Placebo will take by mouth 5 grams a day of placebo powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
This invention relates generally to composites comprising a plurality of nanostructures, and methods of making the same. In some embodiments, the composites further comprise a polymer. In some embodiments, the composites may have desirable properties such as, for example, biodegradability, biocompatibility, and/or high tensile strength. In one embodiment, the plurality of nanostructures comprises carbon nanotubes, and the polymer comprises a poly(beta-amino ester). Various methods are provided for preparing the composites. For example, the polymer and the plurality of nanostructures may, in some embodiments, be combined in a layer-by-layer process to form the composite. High throughput methods for preparing composites having different compositions also are provided for screening composites for desirable properties.
This study will be a randomized (1:1; PCC vs. plasma), open-label trial of hemostatic therapies during heart transplantation. The goal is to enroll 60 patients. Informed consent will be obtained from patients meeting the inclusion and exclusion criteria before the initiation of any study specific procedures. Eligible patients will be randomized to receive either PCC or plasma transfusion. The efficacy of interventions will be evaluated after 30 minutes of protamine administration. After the heart transplantation, thrombocytopenia and/or hypofibrinogenemia may worsen bleeding associated with vitamin K dependent factor deficiencies. Transfusion of platelets and/or cryoprecipitate is permitted if abnormal laboratory values are observed during the rewarming phase of CPB; platelet count \<100 x 103/µl, and fibrinogen \<200 mg/dl, respectively. Laboratory tests (hematocrit, platelet count, PT, PTT, POC-PT, coagulation factor and inhibitor levels (e.g., factor II, antithrombin), thromboelastometry or thromboelastography, endogenous thrombin generation) will also be obtained at baseline, twice during surgery and at 12-24 hours after surgery.
The invention relates to an acne-removing composition and application thereof, belonging to the technical field of cosmetics. The acne-removing composition comprises the following components in parts by weight: 10-15 parts of salvia miltiorrhiza extract, 10-15 parts of scutellaria baicalensis extract, 10-15 parts of cortex mori extract, 10-15 parts of liquorice extract, 20-25 parts of propolis extract, 5-8 parts of sulfur, 8-12 parts of cynanchum paniculatum extract and 8-12 parts of lithospermum extract. The invention also relates to application of the acne-removing composition. The invention also relates to an acne-removing gel and a preparation method thereof. The invention also relates to acne-removing cream and a preparation method thereof. The acne-removing composition disclosed by the invention is prepared from natural traditional Chinese medicine raw materials, is high in safety, has the characteristic of multi-target combined action, and can achieve a very obvious acne-removing effect after being used for 2-3 weeks.
The invention discloses a biomarker NRP1 and application thereof in diagnosis, prevention and treatment of pulmonary fibrosis (including but not limited to pulmonary fibrosis)Not limited to Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Fibrosis due to infection, inflammation, tumor, etc.) and/or asthma, for use in diagnosing and/or treating and/or prognosing the severity of Pulmonary Fibrosis and/or asthma. The invention also provides NRP1 antagonists, inhibitors, modulators, antibodies, pharmaceutical compositions and uses thereof. The invention also provides a detection reagent/kit containing the biomarker NRP1. The invention also provides Il5  Cre  Nrp1  f/f  And Id2  Cre‑ERT2  Nrp1  f/f  A mouse lung inflammatory disease model and application thereof. The invention has wide application prospect in the field of pulmonary fibrosis and/or asthma treatment.
Those allocated to the intervention arm, all the oocytes will be exposed to spermatozoa for 2 hours and gently wash through two organ dishes containing 1.5 ml of equilibrated medium, and then transferred to the corresponding microdroplet of equilibrated fresh medium. Surrounding cumulus cell will be retained, not removed from the ooctyes.
FIELD: veterinary pharmacology, veterinary therapy. SUBSTANCE: a product consists of biologically active substances extracted from bee glue, dimexide and synthetic polyethylenoxides: high-molecular carbowax and low-molecular oligomer combined as adsorptive fusion. Ratio of components, wt%: 5-15 bee glue, 5-15 dimexide, 10-30 high-molecular polyethylenoxide, about 100 low-molecular polyethylenoxide. Preparation is obtained by extraction with absolute dimexide at 60-70 C at intensive mixing at two-stage process: main extraction for 1 hour and additional one after extract removal for 1 hour, also. In precipitated and forming extract polyethylenoxides are dissolved at the same temperature. Bee glue is obtained as medicinal forms: liniment, ointment, suppository. The type of medicinal form depends upon polyethylenoxide type (molecular weight) used and quantitative ratio against other components. As for the technology it is simplified and accelerated. Biologically active substances of bee glue based upon dimexide-molymer are of high cutaneous penetration, mucous. The product is hygienic. EFFECT: higher efficiency. 2 cl, 4 cl, 6 tbl
Fetal alcohol spectrum disorders (FASD) are a group of conditions that can occur in a person whose birth mother consumed alcohol during pregnancy. The effects can include physical problems and/or difficulties with behavior and learning. When clinicians identify FASD early, intervention approaches can minimize the potential impact and lessen or even prevent disabilities. Thus, objective markers for prenatal alcohol exposure are desired.

Using dried blood spots from the umbilical cord and a heel stick of newborns, this study will use Phosphatidylethanol (PEth), a novel biomarker for alcohol exposure, to identify and characterize infants' exposure to alcohol before birth. Additionally, the dried blood spots will used to validate the use of screening assays using epigenetic changes as markers for prenatal alcohol exposure. Epigenetic changes are heritable changes in DNA that affect DNA function but do not change DNA sequence. The use of PEth testing will allow for the correlation of prenatal alcohol exposure levels with epigenetic changes. Women will be consented prior to delivery for participation in this prospective study. The study will be conducted in collaboration with United States Drug Testing Laboratories, Inc. (USDTL).
MAD cohorts 1-4. Subjects in each cohort will be randomized to receive multiple oral doses of ATH-063 (Capsule) under fasting conditions once daily (QD) for 10 consecutive days at planned dose levels.
The present invention relates to the field of therapeutics and in particular to pharmaceutical compositions for the prevention and/or treatment of bacterial infections. The compositions of the present invention demonstrate a synergistic effect in inhibiting the growth of the most clinically relevant Gram-positive bacterial species, and resistant clinical isolates thereof (e.g. MRSA). The two combinations illustrate two novel principles in antimicrobial treatments, using non-antibiotic drugs as adjuvants and decoupling known fixed-dose combinations to repurpose their individual members in novel combinations. The combinations demonstrated a strong synergistic inhibitory effect on the growth, the killing activity and the  in vivo  infection outcome of clinically relevant Gram-positive pathogens, such as MRSA. Importantly, this invention relates to combinations that target multi-drug resistant strains, constituting a major effort of antimicrobial therapy development in the current antimicrobial resistance crisis.
Guidance® UTI pathway with antibiotic sensitivity and microbial testing results reporting to a clinical lead specialist at the urology office within 14 hours of lab receipt. Includes confirmation by the clinical lead that the ordering provider has acted upon results as soon as they are made available. Treatment based on local standard clinical antibiotic selection with or without empiric therapy.
PURPOSE: To report three cases of aneurysmal type 2 neovascularization (AT2), a novel entity within the pachychoroid disease (PD) spectrum.
METHODS: We conducted an observational retrospective study of three patients with subretinal polyps treated with intravitreal aflibercept. We reviewed clinical and imaging data of the three patients. Best corrected visual acuity (BCVA), central macular thickness (CMT), choroidal subfoveal thickness, choroidal thickness under the polyps and the presence of a dry macula were assessed at baseline and throughout the follow-up.
RESULTS: All of the patients showed granular hypoautofluorescence on fundus autofluorescence. Indocyanine green angiography revealed prominent hyperfluorescent branching vascular networks ending in multiple aneurysmal dilatations. Optical coherence tomography (OCT) demonstrated that the aneurysmal lesions were localized in the subretinal space. Additionally, OCT showed retinal pigment epithelial microtears, the double-layer sign and pachyvessels. En face OCT-A perfectly defined prominent telangiectatic branching vascular networks in all the patients, but only revealed polyps in two out of the three patients. Cross-sectional OCT-A demonstrated polyps as patchy circular hypoflow signals in each case. After the intravitreal treatment, BCVA remained unimproved in all of the patients, despite decreased CMT and achievement of a dry macula, as a result of the development of subretinal fibrosis.
CONCLUSION: In summary, we describe a new entity within the spectrum of PD, which we have termed AT2. This novel disease is characterized by the presence of aneurysmal dilatations in the subretinal space, along with the typical features of PD, such as choroidal vascular hyperpermeability, thickening of the choroid and pachyvessels.
Individuals recruited into clinical trials for life-threatening illnesses are particularly vulnerable and this is especially true in low-income settings. The decision to enrol may be influenced by existing inequalities, a poor healthcare infrastructure and the fear of death. Where patients are confused or unconscious the responsibility for this decision falls on the relatives. The objectives of this study are to learn from the experience of participants, relatives and researchers involved in a randomised controlled trial, AMBITION (ISRCTN 72509687), which is testing a novel treatment approach for HIV-associated cryptococcal meningitis and is recruiting participants from multiple sites across sub-Saharan Africa.

The investigators will collect data from trial participants and their relatives who provided consent on their behalf in Gaborone, Botswana; Kampala, Uganda and Harare, Zimbabwe. Interviews will follow a narrative approach and encourage the drawing of timelines. This will be supplemented by direct observation of the research process at each of the three recruiting hospitals. In addition, interviews will take place with researchers from the African and European institutions that form the partnership through which the trial is administered. Findings from the interviews will be prospectively fed back to the individual sites and Trial Management Group to improve the ongoing trial.
PROBLEM TO BE SOLVED: To obtain an ischemic brain disease improving agent, having excellent improving activity on memory disturbance in study by compounding a specific compound separated from Hericium erinaceum as an active component. SOLUTION: This agent contains a chroman derivative of the formula (R is a residue of palmitie acid, stearic acid or linoleic acid, whose carboxyl group is removed). Three kinds of chroman derivatives of the formula are obtained by the following process. Raw or dried fruit bodies of Hericium erinaceum are extracted with a homogeneous solvent system consisting of water and an organic solvent, the extraction mixture is subjected to solid-liquid separation such as filtration to collect the extraction liquid, and the organic solvent is removed by evaporation from the extraction liquid to obtain an aqueous phase. Subsequently, the aqueous phase is subjected to liquid-liquid partitioning extraction with a mixed system of water and an organic solvent to fractionally collect an organic solvent layer, and the organic solvent is removed by evaporation from the organic solvent layer to obtain a dried solid. The dried solid is subsequently treated by fractional chromatography, and the chromatography fractions are further subjected to a re-fractionational treatment to isolate each of the three compounds. The ischemic brain disease improving agent can be formulated into an oral agent such as a tablet or a capsule, or a parenteral agent such as an injection or a liquid agent for eye drop.
Fentanyl buccal tablet contains fentanyl, a Schedule II controlled substance. As an opioid, fentanyl buccal tablet exposes users to the risks of addiction, abuse, and misuse [see Drug Abuse and Dependence (9)].

Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed fentanyl buccal tablet. Addiction can occur at recommended dosages and if the drug is misused or abused.

Assess each patient's risk for opioid addiction, abuse, or misuse prior to prescribing fentanyl buccal tablet, and reassess all patients receiving fentanyl buccal tablet for the development of these behaviors and conditions. Risks are increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). The potential for these risks should not, however, prevent the proper management of pain in any given patient. Patients at increased risk may be prescribed opioids such as fentanyl buccal tablet, but use in such patients necessitates intensive counseling about the risks and proper use of fentanyl buccal tablet along with frequent reevaluation for signs of addiction, abuse, and misuse. Consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2), Warnings and Precautions (5.2)].

Opioids are sought for nonmedical use and are subject to diversion from legitimate prescribed use. Consider these risks when prescribing or dispensing fentanyl buccal tablet. Strategies to reduce these risks include prescribing the drug in the smallest appropriate quantity and advising the patient on careful storage of the drug during the course of treatment and proper disposal of unused drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.